About PeptidesBeat
PeptidesBeat is an editorial publication covering therapeutic peptides — the regulatory landscape, the research base, the supply chain, and the practical questions people and clinicians face when they encounter the category for the first time.
We launched in April 2026, the same week the FDA removed twelve peptides from Category 2 of the 503A compounding evaluation framework. That action was the largest single regulatory shift in the category in over a decade. The July 2026 Pharmacy Compounding Advisory Committee meeting will finalize the 503A Bulks List placement of those twelve compounds. Between those two dates, the entire peptide industry is repositioning. Our job is to cover it accurately while it happens.
Who we are
PeptidesBeat publishes under an organizational byline — the PeptidesBeat Editorial Desk — rather than under personal author names. This is deliberate. The editorial process behind every piece is a small team's, not a single voice's; the responsibility for accuracy and standards belongs to the publication, not to a personality.
We work with licensed clinical reviewers on a contracted basis to review compound pillars and regulatory analysis pieces before publication. Reviewer credentials are added to the byline of any piece they have signed off on.
How we work
We cover the peptide category the way STAT News covers pharma and biotech, or the way Endpoints News covers drug development. Source-driven. Distinguished from advocacy. Distinguished from sales copy. Distinguished from forum speculation. We cite primary sources — Federal Register notices, peer-reviewed literature, state board rulings, court filings — and we mark the difference between preclinical evidence and human clinical evidence on every page where that distinction matters.
We do not write dosing guidance. Dosing decisions belong between a patient and a licensed prescriber who has reviewed that patient's history. We do not endorse specific peptides for specific people. We do not prescribe through this site. We do not sell peptides through this site, ever.
How we make money
We publish a free daily brief on substack-style email, an educational product (the 2026 Peptide Law Playbook), a forthcoming paid newsletter tier, and we charge a flat monthly directory listing fee to compounding pharmacies that meet our standards.
We do not accept affiliate commissions from compounding pharmacies. We do not accept sponsored content from peptide-selling telehealth brands. Directory placement is editorial and not for sale; the listing fee covers operational costs of vetting and maintaining the listing and is the same flat amount regardless of where a pharmacy ranks.
The full disclosure of our business model lives in our editorial policy.
Sister publication
Our quarterly research reports are published under PeptideReport.org, a sister publication. PeptideReport is structurally separate — different site, different infrastructure, different editorial product — and is the home of our long-form analysis work.
Contact
Editorial questions, source tips, factual corrections, and press inquiries: contact page.